Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma

New England Journal of Medicine

Volumn 372, Issue 10, 2015, Pages 944-953

  Robak, Tadeusz ^a   Huang, Huiqiang ^b   Jin, Jie ^c   Zhu, Jun ^d   Liu, Ting ^e   Samoilova, Olga ^g   Pylypenko, Halyna ^j   Verhoef, Gregor ^k   Siritanaratkul, Noppadol ^m   Osmanov, Evgenii ^h   Alexeeva, Julia ⁱ   Pereira, Juliana ⁿ   Drach, Johannes ^o   Mayer, Jiri ^p   Hong, Xiaonan ^f   Okamoto, Rumiko ^q   Pei, Lixia ^r   Rooney, Brendan ^l   Van De Velde, Helgi ^l   Cavalli, Franco ^s  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^e SICHUAN UNIVERSITY   (China)

^f FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^g Nizhny Novgorod Regional Hospital   (Russian Federation)

^h N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

ⁱ Federal Center of Heart   (Russian Federation)

^j Regional Oncological Center   (Ukraine)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^m MAHIDOL UNIVERSITY   (Thailand)

ⁿ UNIVERSITY OF SÃO PAULO   (Brazil)

^o MEDICAL UNIVERSITY OF VIENNA   (Austria)

^p UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^q TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^r JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^s OSPEDALE SAN GIOVANNI   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE; R-CHOP PROTOCOL;

ADULT; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INFESTATION; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LYMPHOMA, MANTLE-CELL; MULTICENTER STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PREDNISONE; PYRAZINES; VINCRISTINE;

EID: 84924439988     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1412096     Document Type: Article

References (36)

1. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27: 511-8.
2. Vose JM. Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2013;88: 1082-8.
3. Williams ME. Transplantation for mantle cell lymphoma: is it the right thing to do? Hematology Am Soc Hematol Educ Program 2013;2013: 568-74.
4. Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol 2014;25: Suppl 3: iii83-iii92.
5. McKay P, Leach M, Jackson R, Cook G, Rule S. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol 2012;159: 405-26.
6. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas, version 5. Fort Washington, PA: National Comprehensive Cancer Network, 2014 (http://www.nccn.org/professionals/physician-gls/f-guidelines.asp).
7. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20: 1288-94.
8. Velcade (bortezomib) for injection: for subcutaneous or intravenous use (package insert). Revision 17. Cambridge, MA: Millennium Pharmaceuticals, October 2014 (http://www.velcade.com/files/pdfs/velcade-prescribing-information.pdf).
9. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-74.
10. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20: 520-5.
11. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007;13: 5291-4.
12. Mounier N, Ribrag V, Haioun C, et al. All B lymphoma subtypes do not share similar outcome after frontline R-CHOP plus bortezomib treatment: a randomized phase 2 trial from the Groupe d'etude des lymphomes de l'adulte (GELA). Ann Oncol 2008;19: Suppl 4. abstract.
13. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25: 579-86.
14. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute (http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf).
15. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111: 2385-7.
16. Garcia M, Romaguera JE, Inamdar KV, Rassidakis GZ, Medeiros LJ. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer 2009;115: 1041-8.
17. Goy A, Bernstein SH, McDonald A, et al. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma 2010;51: 1269-77.
18. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131: 29-38.
19. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111: 558-65. [Erratum, Blood 2008;111: 5761.]
20. Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle- Cell Lymphoma Network. J Clin Oncol 2014;32: 1338-46.
21. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367: 520-31.
22. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014;123: 2944-52.
23. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23: 1984-92.
24. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 noninferiority trial. Lancet 2013;381: 1203-10.
25. Ribrag V, Gisselbrecht C, Haioun C, et al. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 2009 115 4540-6.
26. Furman RR, Martin P, Ruan J, et al. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 2010;116: 5432-9.
27. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29: 690-7.
28. O'Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression- free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol 2009;145: 34-9.
29. Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010;11: 1057-65.
30. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010;51: 1178-87.
31. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12: 431-40.
32. Barbee MS, Harvey RD, Lonial S, et al. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. Ann Pharmacother 2013; 47: 1136-42.
33. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106: 3777-84.
34. Lonial S, Richardson PG, San Miguel J, et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 2008;143: 222-9.
35. Murai K, Kowata S, Shimoyama T, et al. Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes. Eur J Haematol 2014;93: 290-6.
36. Shi DS, Smith MC, Campbell RA, et al. Proteasome function is required for platelet production. J Clin Invest 2014;124: 3757-66.